Novartis’ Entresto Patent Dispute with MSN Pharmaceuticals Highlights Industry Tensions

In a legal confrontation that underscores the stakes in pharmaceutical patent disputes, MSN Pharmaceuticals has criticized Novartis for their approach concerning the patent status of the cardiovascular drug, Entresto. As reported in Law360, MSN filed papers with a Delaware federal court arguing that Novartis is being “disingenuous” in claiming a lack of urgency in determining whether Entresto’s patent should remain in a critical drug database. This dispute emerges amid broader tensions in pharmaceutical patent strategies, highlighting the pivotal financial and competitive implications for stakeholders in the industry.